As a result, pembrolizumab has become the standard treatment of NSCLC for newly diagnosed patients with PD-L1 expression levels ≥ 50% and without EGFR (epidermal growth factor receptor) or ALK (anaplastic lymphoma kinase) positive mutations. This evidence concerns the gene CD274 and non-small cell lung carcinoma.